Valuation
- Market cap
- 745,011,000
- Revenue TTM
- $0
- Net income TTM
- $-54,650,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- -0.60
Trading
- Volume
- 1,886,300
- Avg volume
- 1,465,642
- Day's range
- $7.05 – $7.63
- Shares out
- 102,902,000
- Stochastic %K
- 14%
- Beta
- 2.30
- Analysts
- Strong Sell
- Price target
- $14.36
Company profile
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD an...
Show more
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 604 210 2217
- Website
- https://www.achievelifesciences.com
- Address
- 22722 29th Dr. SE, Suite 100, Bothell, United States
Latest news
No headlines yet.
